Advertisement

Ruckdeschel heads cancer institute at University of Mississippi Medical Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

John Ruckdeschel was named director of the cancer institute of the University of Mississippi Medical Center as well as Ergon Chair in Cancer Research.

Ruckdeschel, who previously served as the director of the Moffitt Cancer Center, led that institution to NCI Comprehensive Cancer Center designation and to become the third largest clinical cancer program in the U.S.

He then moved to the Barbara Ann Karmanos Cancer Center in Detroit where he re-acquired its NCI comprehensive status and completed the process of making Karmanos a freestanding cancer hospital.

His research was originally in basic immunology but gravitated to clinical and translational research in thoracic malignancies. Ruckdeschel’s career has focused on lung cancer and other thoracic malignancies. He is credited with more than 150 peer reviewed manuscripts and co-editorship of the Textbook of Thoracic Oncology. He is a North American Editor for the Cochrane Lung Cancer Review Group.

Ruckdeschel and Terrance Albrecht co-developed a means to effectively video record patient-physician interactions and applied this technology to understanding clinical trials accrual and end of life decision-making.

Advertisement
Advertisement

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
Advertisement
Advertisement